Zydus Lifesciences guides for margin contraction in FY27
Management expects EBITDA margins to drop to 24% from 31.2% as competition intensifies and the company ramps up US commercialization costs.
What's new
- Management targets high-teens revenue growth for FY27.
- Margin pressure stems from Revlimid and Mirabegron competition.
- The company is investing $70 million into the US launch of Saroglitazar.
Why this matters
A margin drop of over 700 basis points is a significant reset for a large-cap pharma. The company is trading current profitability for long-term specialty portfolio growth, specifically through the Saroglitazar launch and the Assertio acquisition.
What we're watching
- The integration timeline for the Assertio Holdings acquisition.
- Market share capture for Saroglitazar in the US.
- Revenue contribution from the newly approved Desidustat in China.
The full read
Zydus Lifesciences is bracing for a leaner year. During its Q4 FY26 earnings call, management guided for high-teens revenue growth in FY27, but signaled a sharp contraction in profitability. EBITDA margins are expected to land above 24%, a significant step down from the 31.2% achieved in the prior year. The company points to two primary headwinds: intensifying competition for Revlimid and Mirabegron, and the heavy upfront costs of launching Saroglitazar in the US. Zydus is pouring $70 million into that commercialization effort alone. Beyond the immediate margin hit, the company is betting on its specialty pipeline to sustain long-term growth. This includes the pending acquisition of Assertio Holdings and the recent approval of Desidustat in China for renal anemia. The strategy is clear: sacrifice near-term margins to fund a broader specialty footprint. Whether that trade-off pays off is the next test for the stock.
Questions answered
- Why are EBITDA margins expected to contract in FY27?
- Margins are expected to fall below 24% from the 31.2% recorded in FY26. This is due to increased competition for key products like Revlimid and Mirabegron, alongside heavy investment in the US launch of Saroglitazar.
- How much is the company spending on the Saroglitazar launch?
- Zydus is committing $70 million to the commercialization of Saroglitazar in the US market.
- What is the status of the company's specialty portfolio?
- The company is moving forward with the acquisition of Assertio Holdings and has secured approval for Desidustat in China for the treatment of renal anemia.
- What is the revenue growth outlook for the upcoming year?
- Management has guided for high-teens consolidated revenue growth for FY27.